Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01607554 · ClinicalTrials.gov registry record · Phase 1
Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01607554: Clinical Trial Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
NCT01607554 is a Phase 1 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01607554, a Phase 1 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Certain genetic factors can affect a patient's potential sensitivity to therapeutic drugs and other agents. There is a factor called ISG15 which might help doctors better identify patients with advanced non-small cell lung cancer (NSCLC) whose tumors may be more sensitive to the drug called Irinotecan. This factor is elevated in roughly 30% of NSCLC cases. Irinotecan is an agent that inhibits the enzyme called topoisomerase I that is involved in cell growth, and it has been FDA approved for 17 years for another type of cancer.
Primary Outcome
Change in tumor size will be measured by CT scan using RECIST criteria.
Interventions
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Why NCT01607554 stopped before completion
NCT01607554 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Irinotecan is the first listed.
NCT01607554 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01607554 about?
NCT01607554 is a clinical study titled "Irinotecan for Previously Treated, Advanced, Non-Small Cell Lung Cancer". Certain genetic factors can affect a patient's potential sensitivity to therapeutic drugs and other agents. There is a factor called ISG15 which might help doctors better identify patients with advanced non-small cell lung cancer (NSCLC) whose tumors may be more sensitive to the drug called Irinotec...
What is the current status of trial NCT01607554?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2012-04. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01607554?
The interventions under investigation include: Irinotecan (DRUG).
Who is sponsoring clinical trial NCT01607554?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01607554's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia